Overseas Studies May Not Be Worth Oversight Costs, Consultants Suggest
This article was originally published in PharmAsia News
Executive Summary
Overseas clinical trials could save companies money, but consultants on a regulatory panel at the Biotechnology Industry Organization's Mid-America VentureForum in Cleveland suggested such studies might not be worth the oversight costs